Mesothelioma is cancer of the thin tissue lining around organs. It most often affects the pleura around the lungs and can affect the abdominal lining. Care depends on its site, extent and the person’s health, with specialist treatment and symptom support. NHS: mesothelioma definition.
- Pleural and peritoneal mesothelioma are different sites, not interchangeable treatment pathways. NCI: mesothelioma sites.
- Major surgery is uncommon and requires careful specialist assessment. NHS: mesothelioma treatment.
- Pleurodesis controls recurring fluid; it is not a tumor-removal operation. CUH: pleurodesis.
- Severe breathing difficulty requires immediate emergency help. NHS: emergency breathlessness.
- Supplements should not replace or delay cancer care. NCCIH: cancer and complementary approaches.
Table of contents
- Evidence summary
- What mesothelioma is: pleural, peritoneal and rare sites
- Diagnosis and biology: tissue, cell type and the actual site
- Treatment pathways: systemic therapy, selected surgery and fluid control
- Supplements and daily support: nutrition, fatigue and symptom care
- What is established and uncertain: surgery evidence and staging limits
- Risks and urgent symptoms: breathing, immune injury and drainage problems
- Interactions: prescriptions, blood thinners and supplements
- Who needs extra assessment: organ function, exposure and family history
- Clinician-led treatment and follow-up: a written plan for changing needs
- Animal and laboratory research: immune signals are not patient benefit
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Diagnosis and site | High descriptive confidence | Public/provider source-chain gaps | Pleural/peritoneal site and tissue type matter. |
| Systemic treatment | Attributed clinical context | PDQ reviewer ties; trials unclosed | No independent drug comparison or personal regimen. |
| Major pleural surgery | Population-limited randomized context | Public/charitable funding; commercial author ties | MARS 2 is a bounded comparison, not all-site surgery evidence. |
| Fluid control | Clinical procedure context | Provider finances/contributor gaps | Pleurodesis and catheter drainage have symptom goals. |
| Supplements | No independent positive verdict | Dated safety education | No replacement or lab-derived regimen established. |
What mesothelioma is: pleural, peritoneal and rare sites
The pleura lines the chest and covers the lungs; the peritoneum lines the abdomen and covers many abdominal organs. Mesothelioma can also arise around the heart or testicular coverings, but those rare sites need separate evaluation. A mesothelial cancer should not automatically be treated as ordinary lung cancer or as a benign pleural abnormality. NCI: mesothelioma sites.
Pleural disease may cause persistent chest pain, breathlessness, cough, fatigue or weight loss. Peritoneal disease may cause abdominal pain or swelling, nausea and bowel changes. These symptoms have other causes, but ongoing unexplained changes should be assessed. Tell the clinician about relevant work history rather than assuming that a common cough proves or excludes this cancer. NHS: mesothelioma symptoms.
Past asbestos exposure is a major risk factor, often associated with construction, shipbuilding or other jobs involving older materials. Disease may appear decades later. A current job without asbestos does not erase earlier exposure; give a history that includes previous workplaces and tasks. This guide does not provide a worldwide asbestos-law or compensation determination. NHS: mesothelioma causes.
Diagnosis and biology: tissue, cell type and the actual site
Investigation may include chest imaging, CT or other selected scans, drainage of fluid and sampling of tissue. Thoracoscopy examines the chest; laparoscopy can examine the abdomen. Not everyone needs every listed procedure. Ask what the proposed test will establish and whether the sample will be sufficient for specialist pathology review. NHS: mesothelioma tests.
Mesothelioma can resemble another cancer in the chest. A pathologist examines cells or tissue and uses appropriate laboratory tests to help distinguish the diagnosis. A second opinion can review the pathology slides, report and scans together. An imaging suspicion or exposure history alone should not be treated as final proof of the tumor type. NCI: mesothelioma diagnosis.
The main histological patterns are epithelioid, sarcomatoid and biphasic, which contains both elements. Tissue type matters to assessment and care. For selected primary peritoneal disease, specialists may consider cytoreductive surgery with heated intraperitoneal chemotherapy (HIPEC); pleural treatment evidence cannot simply be transferred to that abdominal pathway. NCI: professional mesothelioma PDQ.
Fluid around a lung can contribute to breathlessness, while abdominal fluid can cause swelling and discomfort. Fluid is a clinical problem requiring assessment; it does not itself identify the cancer type. Tell the team when the symptom changes, because drainage, tissue investigation and treatment of the underlying cause have different purposes. NCI: mesothelioma symptoms.
Treatment pathways: systemic therapy, selected surgery and fluid control
A specialist team considers site, spread, health and preferences before proposing treatment. Immunotherapy, chemotherapy, radiation and supportive procedures have different roles. The current NHS page describes surgery as rarely used, including selected early disease or symptom relief. Discuss the goal and burden of each option rather than assuming that a technically removable tumor makes major surgery beneficial. NHS: mesothelioma treatment.
For pleural disease, systemic treatment can include chemotherapy or selected immunotherapy combinations; recurrent care depends on previous treatment and current health. This dated clinical source describes options rather than a complete current authorization list. Drug choice and availability need local specialist confirmation; this guide does not independently rank products or give a personal regimen. NCI: mesothelioma treatment.
Peritoneal care is planned separately. Selected people may be assessed for cytoreductive surgery and chemotherapy delivered into the abdomen, including HIPEC. Fitness and disease extent matter, and this is a major procedure rather than a general option for every mesothelioma. Abdominal fluid may be drained for symptom relief. No survival benefit is independently inferred from selected surgical series. CRUK: peritoneal mesothelioma care.
Pleurodesis places a substance into the pleural space to encourage its surfaces to adhere and reduce fluid or air reaccumulation. Its goal is fluid control and relief of related symptoms, not removal of all cancer. The team assesses whether it fits the lung’s condition and the patient’s needs; it does not work for everyone. CUH: pleurodesis.
An indwelling pleural catheter allows repeated drainage when fluid recurs. The service teaches the patient, a carer or community nurses how to manage it and sets an appropriate drainage plan. Do not select the amount or frequency from another person’s experience. Drainage can ease a fluid-related symptom without establishing that the cancer has responded. CUH: indwelling pleural catheter.
Supplements and daily support: nutrition, fatigue and symptom care
Chest or abdominal symptoms, nausea and altered appetite can reduce intake. Report weight loss, difficulty eating or persistent vomiting rather than imposing a restrictive cancer diet. A dietitian can adapt intake to symptoms and treatment. Adequate nutrition supports the person; a dietary attempt to “starve” mesothelioma is not established tumor treatment. NCI: appetite and nutrition.
Fatigue may have several contributors, including anemia, poor sleep, pain and reduced nutrition. Describe its pattern and what daily tasks have become difficult. The team can assess these problems and adapt activity or rest to current function. New breathlessness or a major decline should not simply be attributed to expected fatigue. NCI: cancer fatigue.
Palliative care supports pain, breathlessness, distress and practical needs alongside oncology treatment. It does not require all cancer-directed care to stop. Request support when symptoms or daily limitations are burdensome; relatives and carers may also need help. Decisions should reflect the patient’s priorities as well as the burden of travel, procedures and treatment. NCI: palliative care.
What is established and uncertain: surgery evidence and staging limits
The 2024 MARS 2 randomized trial reported worse survival to two years and more serious adverse events when extended pleurectomy decortication was added to chemotherapy in its resectable pleural population. This open-label comparison does not answer every surgery question or establish outcomes for peritoneal mesothelioma. Its commercial author ties and public/charitable funding remain disclosed. MARS 2: original 2024 randomized trial.
The stage framework on this NCI page describes pleural extent, lymph nodes and distant spread. Do not automatically assign the same stage meaning to a primary abdominal tumor. Ask the team which staging system applies, what uncertainty remains and how the findings affect the plan. A stage number cannot predict one person’s survival. NCI: mesothelioma stages.
Exposure increases risk but does not mean that everyone exposed will develop mesothelioma. Some diagnoses have no recognized exposure history. A household contact may also matter when asbestos was carried home from work. Reconstructing that history can inform assessment, but cannot establish an individual cause or liability from a generic article. NCI: mesothelioma risk context.
Trials can study systemic treatment, symptom care or new combinations. Discuss eligibility, sponsor, comparison, additional tests and alternatives. A trial listing is not proof that the intervention works or that finance is independent. No manufacturer-funded outcome is adopted here as an independent positive efficacy verdict. NCI: clinical trials.
Risks and urgent symptoms: breathing, immune injury and drainage problems
Seek immediate emergency help for severe breathing difficulty, gasping or inability to get words out, a tight or heavy chest, sudden confusion, or very pale, blue or grey lips or skin. Do not wait for the next scan or first decide whether mesothelioma is responsible. Breathlessness has several potentially urgent causes. NHS: emergency breathlessness.
Immunotherapy can activate immune injury in healthy tissues, including organ inflammation. Side effects may appear during or after treatment and can occasionally be severe. Ask for the actual drug’s warning signs and report new breathing trouble, persistent diarrhea, marked weakness or other concerning changes. Feeling well after an infusion does not guarantee that later symptoms are unrelated. NCI: immunotherapy side effects.
With a pleural catheter, fever or increasing redness, swelling, oozing or pain needs prompt contact with the pleural team. A new lump or persistent pain around the tube should also be reported. Follow the taught care and hygiene plan rather than manipulating a blocked or displaced catheter independently. CUH: indwelling pleural catheter.
When treatment weakens infection defenses, fever, chills or sudden illness can require urgent oncology contact. Use the service’s emergency instructions and keep its number accessible. Do not wait for a routine appointment or first conceal a possible fever with nonprescription medicine without discussing what to do. NCI: infection during cancer treatment.
Radiation effects depend on the treated area. Chest treatment can affect swallowing or breathing, while abdominal treatment can affect the bowel and intake. Some effects develop later. Report persistent or new problems so the team can assess them instead of assuming that every symptom is either recurrence or an inevitable treatment effect. NCI: radiation side effects.
Interactions: prescriptions, blood thinners and supplements
Before thoracoscopy, tell the team about anticoagulants, antiplatelet medicines and diabetes treatment. Procedure-related bleeding and clotting risks require individual decisions. A public leaflet’s drug-hold or fasting schedule should not be copied without the team’s instructions, especially if another clinician has advised that a medicine must continue. CUH: medical thoracoscopy.
Provide all prescription and nonprescription medicines, herbs, extracts and supplements to the oncology pharmacist. Food and plant products can alter anticancer medicines; St John’s wort is one example, but the risk depends on the actual drug. “Natural” labeling does not establish compatibility or supply a safe timing interval. NCI: food and supplement interactions.
Who needs extra assessment: organ function, exposure and family history
Treatment planning considers the specific cells, extent and general health, including lung and heart function. Significant symptoms or functional limitations should be described before a procedure or systemic therapy is chosen. Ask why the expected benefit and burden fit this situation; a population prognosis or another person’s fitness cannot replace individual assessment. NCI: mesothelioma diagnosis.
Asbestos-related lung scarring, pleural changes, lung cancer and mesothelioma are different conditions. Smoking does not explain mesothelioma in the same way it affects lung-cancer risk. The dated NCI source also recognizes inherited BAP1 variation as a risk factor. Discuss relevant personal and family history with specialists; this does not justify routine consumer genetic testing or predict disease from one result. NCI: asbestos and cancer risk.
Bring the actual exposure history, pathology report and complete medication list to assessment. Ask whether expert pathology or another specialist opinion would change the plan. Clarify transport, home support and catheter supplies before a procedure, especially when symptoms make self-care difficult.
Clinician-led treatment and follow-up: a written plan for changing needs
Chemotherapy monitoring may include symptoms, blood counts, measurements and scans. Fever, infection signs, a painful swollen limb or sudden chest/breathing symptoms require timely assessment for complications. The care team decides dose and timing from the actual regimen and health status; do not change treatment because a general leaflet gives a different schedule. NHS: chemotherapy monitoring.
During and after care, tests or scans assess response or change and help guide treatment decisions. Ask which symptoms should trigger earlier contact. Recurrent disease requires assessment of prior therapies and current health; no universal follow-up calendar or guaranteed response is given here. NCI: mesothelioma treatment.
Keep the pathology subtype, site, stage, treatment summary and emergency contacts together. Useful questions include: Is this pleural or peritoneal disease? Is the goal tumor control or symptom relief? What is the evidence for this operation in my situation? What should we do if breathing or catheter symptoms change? Who coordinates care between visits?
Animal and laboratory research: immune signals are not patient benefit
Cell and animal experiments can suggest mechanisms without proving a safe human dose, tumor control or longer survival. Human studies need defined populations, suitable comparisons and meaningful outcomes. A laboratory immune signal or tumor-cell effect should not be converted into a supplement regimen or a reason to delay diagnostic tissue sampling. NCI: research phases.
No supplement cure or replacement for mesothelioma care is established here. Correcting a documented deficiency can address a separate medical need with clinician advice; it does not establish anticancer efficacy. Discuss products before use, particularly when they might interact with treatment or delay an urgent oncology or breathing assessment. NCCIH: cancer and complementary approaches.
Funding and source roles
Research funding at a glance
43 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHS: mesothelioma definition | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | B provisional. Reviewed 26 March 2026. Public-service and institutional incentives; no independently cleared product outcome. |
| NHS: mesothelioma symptoms | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | B provisional. Reviewed 26 March 2026. Public-service and institutional incentives; no independently cleared product outcome. |
| NHS: mesothelioma causes | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | B provisional. Reviewed 26 March 2026. Public-service and institutional incentives; no independently cleared product outcome. |
| NHS: mesothelioma tests | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | B provisional. Reviewed 26 March 2026. Public-service and institutional incentives; no independently cleared product outcome. |
| NHS: mesothelioma treatment | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | B provisional. Reviewed 26 March 2026. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: mesothelioma sites | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 16 May 2025. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: mesothelioma symptoms | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 16 May 2025. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: mesothelioma risk context | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 16 May 2025. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: mesothelioma diagnosis | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 16 May 2025. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: mesothelioma stages | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 16 May 2025. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: mesothelioma treatment | NCI routes below. Related professional leads have dated ties below; current page lacks an explicit derivation statement or named reviewer. Direct page payments unknown. | United States; NCI, Bethesda, Maryland | Tier 3 — linked clinical-family provenance; provisional | C provisional. Updated 16 May 2025. Clinical context; direct authorship/derivation and supporting-trial finance unclosed. |
| NCI: professional mesothelioma PDQ | NCI routes below. Leads: Dancey, Rajan, Szabo. Dated commercial relationships and maker-connected research below; personal/page payments and original-study chains unclosed. | United States; NCI, Bethesda, Maryland | Tier 3 — connected reviewer provenance; clinical context | C provisional. Updated 12 May 2025. PDQ is not a formal guideline; no independently ranked drug outcome. |
| NCI: asbestos and cancer risk | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Reviewed 20 May 2021. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: immunotherapy side effects | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Reviewed 16 February 2023. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: radiation side effects | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Reviewed 15 May 2025. Public-service and institutional incentives; no independently cleared product outcome. |
| NHS: emergency breathlessness | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | B provisional. Reviewed 30 January 2024. Public-service and institutional incentives; no independently cleared product outcome. |
| NHS: chemotherapy monitoring | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | B provisional. Reviewed 14 February 2025. Public-service and institutional incentives; no independently cleared product outcome. |
| CUH: indwelling pleural catheter | See CUH’s own accounts below; leaflet allocation, named contributors’ outside interests and trial finance remain unclosed. | United Kingdom; CUH, Hills Road, Cambridge | Tier 2 — clinical context; provisional | B provisional. Approved 3 February 2026, version 8. Public-service and institutional incentives; no independently cleared product outcome. |
| CUH: pleurodesis | See CUH’s own accounts below; leaflet allocation, named contributors’ outside interests and trial finance remain unclosed. | United Kingdom; CUH, Hills Road, Cambridge | Tier 2 — clinical context; provisional | B provisional. Approved 7 April 2026, version 7. Public-service and institutional incentives; no independently cleared product outcome. |
| CUH: medical thoracoscopy | See CUH’s own accounts below; leaflet allocation, named contributors’ outside interests and trial finance remain unclosed. | United Kingdom; CUH, Hills Road, Cambridge | Tier 2 — clinical context; provisional | B provisional. Approved 19 August 2026, version 8. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: appetite and nutrition | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Actual body read; date not separately closed. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: cancer fatigue | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Reviewed 20 September 2024. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: infection during cancer treatment | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Reviewed 23 January 2020. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: palliative care | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Actual body read; date not separately closed. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: food and supplement interactions | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 25 April 2024. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: clinical trials | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 3 November 2024. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: research phases | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 8 November 2024. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI budget | Congressional appropriations through NIH/HHS. The dated page distinguishes enacted funding from requests; it does not allocate money to this disease page. | United States; NCI, Bethesda, Maryland | Tier 3 — institutional financial/process self-report | B provisional. Institutional budget self-report, updated 14 May 2026; statutory scrutiny and an incentive to explain its public mission. |
| NCI Gift Fund and contributions | NCI accepts public donations through its Gift Fund; stamp-related public support is separate. No current disease-page donor ledger or corporate payment is established here. | United States; NCI, Bethesda, Maryland | Tier 3 — institutional financial/process self-report | B provisional. Own contribution information, updated 27 August 2025; fundraising incentives. Donation authority does not prove a named donor funded a page. |
| NCI website editorial process | The website describes expert and editorial review. Its current public budget and gift routes are listed separately; the process page does not supply contributor contracts. | United States; NCI, Bethesda, Maryland | Tier 3 — institutional financial/process self-report | B provisional. Own editorial-process account, reviewed 24 February 2025; institutional credibility incentives. Financial independence of underlying studies remains unknown. |
| PDQ editorial boards and conflicts | NCI provides nongovernment board members honoraria and travel reimbursement. Conflict declarations and recusal are required, but specific board conflicts are not published. | United States; NCI, Bethesda, Maryland | Tier 3 — institutional financial/process self-report | B provisional. Own process disclosure, updated 1 November 2022. Editorial autonomy is distinct from financial independence; current personal and original-trial chains remain incomplete. |
| NHS national website content policy | The dated national policy identifies DHSC funding and states no advertising or corporate sponsorship; it describes staff/contractor declarations. No individual provider finances are established. | England, United Kingdom; national website jurisdiction | Tier 3 — institutional financial/process self-report | B provisional for the dated self-report. Reviewed 14 October 2022; review due 14 October 2025 has passed. Later restructuring, page allocations and source-study ties are not cleared. |
| NCCIH FY2025 congressional justification | NIH/HHS federal budget route. This historical request is not an enacted current budget; the page explicitly says it no longer reflects current HHS policy. Gifts and page allocation remain unclosed. | United States; NCCIH, Bethesda, Maryland | Tier 3 — institutional financial/process self-report | B provisional for historical institutional self-report; budget-advocacy incentives. The proposal cannot establish present appropriations or supplement efficacy. |
| NCCIH: cancer and complementary approaches | See the historical NCCIH fiscal source above; exact education-page allocation, expert interests, and each cited study’s finance are unresolved. | United States; NCCIH, Bethesda, Maryland | Tier 2 — public safety context; provisional | C provisional. Last updated October 2021, distinct from the website footer. Public safety education and institutional incentives; dated synthesis does not independently establish any product outcome. |
| CUH: FY2025–26 audited accounts | NHS commissioning, private/overseas care, research/training, charitable capital and other income; industry/academic partnerships. Leaflet allocations unknown. | United Kingdom; NHS Foundation Trust, Cambridge | Tier 3 — statutory financial self-report | B provisional. Notes 2.1–2.3 and partnership text actually read; service/commercial/budget incentives. |
| Dancey: 2019 original author disclosures | The 2019 declaration lists Dancey’s Roche Canada/Sanofi Canada consulting, 3Ci leadership/honoraria, and research support marked institutional from Pfizer, Merck, AstraZeneca and others. The paper names EORTC and Canadian Cancer Society research funds; their upstream backers remain unclosed. | International paper; Dancey at Queen’s University, Kingston, Canada; Dutch repository is a host | Tier 3 — dated commercially connected author self-report | B provisional for reported financial relationships. Original JCO publisher PDF, DOI 10.1200/JCO.18.01100; 2019 publication, not a 2025 disclosure. Accuracy incentives include journal scrutiny; declaration completeness and current payments unknown. |
| 2023 PT-112 abstract: reviewer financial disclosures | NIH/NCI intramural support plus a Promontory Therapeutics CRADA; Rajan reports Promontory research funding to his institution. Company-affiliated coauthors report equity/support. McAdams and Szabo are among authors covered by the remaining-authors no-conflicts statement. | United States; NCI, Bethesda, and Promontory, New York; publisher in Hong Kong, China | Tier 4 — maker-connected trial report; financial context only | D for self-interested treatment evidence, excluded here. Original 2023 abstract/financial footnote, DOI 10.21037/med-23-ab016. Disclosure is useful but self-reported; separate full forms were inaccessible. Current PDQ or personal payments are not established. |
| Rajan/Szabo: May 2026 financial declarations | Article names NCI intramural support. Rajan declares Promontory research funding to his institution; Szabo covered by remaining-authors no-conflict statement. Personal/page payments and current contracts unclosed. | United States; NCI, Bethesda; Promontory, New York | Tier 3 — commercially connected author self-report | B provisional for named statement, 20 May 2026. No maker funding of this particular descriptive article inferred; self-declaration is bounded. |
| MARS 2: original 2024 randomized trial | NIHR HTA, CRUK feasibility and Mesothelioma UK participant expenses. Authors declare company grants/fees, patents and business interests, including Lim. Abstract/acknowledgment grant IDs differ; receipt ledger unclosed. | United Kingdom; London/Bristol and participating UK centers | Tier 3 — commercially connected authors; mixed public/charitable finance | C provisional. June 2024 issue, open-label randomized design. Funder non-involvement self-statement; no direct maker trial funding inferred. |
| NIHR: MARS 2 award record | Own record identifies award 15/188/31, Eric Lim, May 2017–July 2023. Award is not a receipt ledger or author financial clearance. | United Kingdom; NIHR public research funding | Tier 3 — funder financial/process self-report | B provisional for indexed original award record. Direct page renders a shell; complete disbursement and amendment history unclosed. |
| NIHR: own institutional funding route | Own service states NIHR and this service are DHSC-funded; research collaborations include public funders, charities and industry. Complete revenue/gift and trial allocation ledger unclosed. | United Kingdom; NIHR/DHSC | Tier 3 — institutional funding/process self-report | B provisional. Actual current body read; update date not separately closed. Public accountability and recruitment/policy incentives. |
| CRUK: FY2025–26 own financial summary | Gifts/Wills, philanthropic and corporate partnerships, events, trading, intellectual-property licensing, investments and other income. Exact pilot donor allocation unclosed. | United Kingdom; registered charitable company, 2 Redman Place, London | Tier 3 — institutional financial self-report | B provisional for actual 2025–26 summary. Fundraising, licensing and institutional incentives; full donor/receipt ledger not audited here. |
| CRUK: peritoneal mesothelioma care | See CRUK finance below. Page acknowledges Dangoor Education support since 2010; sponsor’s own site unavailable, upstream origin and page/author/study allocations unclosed. | United Kingdom; charitable publisher, London; sponsor jurisdiction unclosed | Tier 2 — charity clinical context; provisional | C provisional. Reviewed 24 May 2023; May 2026 review overdue. Education/fundraising incentives; no independent HIPEC survival estimate. |
Frequently asked questions
Is pleural mesothelioma the same as ordinary lung cancer? No. It begins in the pleural lining; the diagnosis and pathway differ from a primary cancer within the lung. NCI: mesothelioma sites.
Does asbestos exposure mean I will develop mesothelioma? No. It increases risk, but not every exposed person develops the disease; some diagnoses have no known exposure. NCI: mesothelioma risk context.
Does pleurodesis remove mesothelioma? No. It aims to control recurring fluid or air in the pleural space, rather than remove the tumor. CUH: pleurodesis.
Does every mesothelioma need major surgery? No. Surgery is uncommon and needs careful specialist assessment for the particular site and situation. NHS: mesothelioma treatment.
Should severe breathlessness wait for the next cancer scan? No. Severe difficulty breathing, blue or grey lips, a tight chest or sudden confusion needs immediate emergency help. NHS: emergency breathlessness.
Can supplements replace mesothelioma treatment? No replacement is established here. Discuss products and avoid delaying cancer or urgent breathing care. NCCIH: cancer and complementary approaches.
Sources and funding notes
Reviewed 4 October 2026. This malignant adult overview does not close separate childhood, peritoneal, pericardial, testicular-covering or rare histological entity guides. Current public treatment URL redirects from former patient PDQ and lacks an explicit professional-derivation statement; linked-family concerns do not establish direct page payment. Dated and current reviewer records are separated. Clinical pathways are attributed, sponsor-funded product outcomes excluded and personal regimens omitted. MARS 2 is a specific pleural comparison; its qualitative result is not extrapolated to all surgery or another primary site. Institutional education and funder self-reports do not close supporting-study or donor receipt chains.
- NHS: mesothelioma definition — Mesothelial lining, sites and individualized seriousness.
- NHS: mesothelioma symptoms — Pleural versus abdominal presentation and assessment.
- NHS: mesothelioma causes — Past asbestos exposure and long latency.
- NHS: mesothelioma tests — Imaging, fluid/tissue sampling and results pathway.
- NHS: mesothelioma treatment — Specialist planning, systemic care and uncommon surgery.
- NCI: mesothelioma sites — Pleural/peritoneal and rare-site boundaries.
- NCI: mesothelioma symptoms — Fluid-related chest and abdominal symptoms.
- NCI: mesothelioma risk context — Occupational/household exposure and risk versus certainty.
- NCI: mesothelioma diagnosis — Tissue review, differential diagnosis and second opinion.
- NCI: mesothelioma stages — Pleural staging and anatomic spread; no site-wide stage equivalence.
- NCI: mesothelioma treatment — Selected systemic/recurrent care and follow-up; no authorization list.
- NCI: professional mesothelioma PDQ — Histological types and selected peritoneal care; observational survival estimates excluded.
- NCI: asbestos and cancer risk — Dated carcinogen, smoking and inherited-risk distinctions; current legal rules excluded.
- NCI: immunotherapy side effects — Immune injury can occur during or after treatment; no adverse-event estimate.
- NCI: radiation side effects — Chest/abdominal field-specific and late effects.
- NHS: emergency breathlessness — Severe breathing difficulty and emergency assessment.
- NHS: chemotherapy monitoring — Blood-count, clot and infection safety; individualized monitoring.
- CUH: indwelling pleural catheter — Guided drainage, training and catheter infection warnings.
- CUH: pleurodesis — Fluid-control purpose and limitations; no tumor-eradication claim.
- CUH: medical thoracoscopy — Tissue sampling, bleeding-risk and diabetes planning; no generic drug holds.
- NCI: appetite and nutrition — Symptoms, intake and dietitian assessment.
- NCI: cancer fatigue — Assessment of contributing problems; no activity prescription.
- NCI: infection during cancer treatment — Dated urgent infection precautions; personal instructions take priority.
- NCI: palliative care — Symptom and practical support alongside treatment.
- NCI: food and supplement interactions — Drug-specific interaction precautions; individual editor/trial finance unclosed.
- NCI: clinical trials — Research participation is not established personal benefit.
- NCI: research phases — Human safety/outcome research versus preclinical signals.
- NCI budget — Institutional finance only; not treatment efficacy or author clearance.
- NCI Gift Fund and contributions — Additional institutional funding route and headquarters; no page allocation inferred.
- NCI website editorial process — Editorial process only; not an efficacy study.
- PDQ editorial boards and conflicts — PDQ process and financial limits; PDQ summaries are not formal clinical guidelines.
- NHS national website content policy — National website funding/editorial policy, not hospital accounts or current author contracts.
- NCCIH FY2025 congressional justification — Dated institutional route only; no current expenditure total or private-gift exclusion.
- NCCIH: cancer and complementary approaches — Dated replacement/delay and supplement-interaction safety context; no independent product efficacy verdict.
- CUH: FY2025–26 audited accounts — Provider revenue only; no contributor or trial clearance.
- Dancey: 2019 original author disclosures — Named professional-PDQ reviewer finance only; no RECIST outcome or oncology efficacy adopted.
- 2023 PT-112 abstract: reviewer financial disclosures — Dated reviewer research-finance audit only; no trial response, safety or treatment estimate adopted.
- Rajan/Szabo: May 2026 financial declarations — Current reviewer provenance only; thymic-cancer clinical results excluded.
- MARS 2: original 2024 randomized trial — Bounded surgery comparison; no peritoneal, all-surgery or product extrapolation.
- NIHR: MARS 2 award record — Grant identity/dates only; no trial outcome adopted from award synopsis.
- NIHR: own institutional funding route — Institutional route only; collaboration does not prove maker funding of MARS 2.
- CRUK: FY2025–26 own financial summary — Charity revenue route only; not MARS 2 author or outcome clearance.
- CRUK: peritoneal mesothelioma care — Separate abdominal-site pathway and ascites support; treatment efficacy ranking excluded.
Educational research reviewed 4 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.